Last quarter (Q4 2023), Elevation Oncology's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Elevation Oncology's net income was $-7.90M. See Elevation Oncology’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 40.34M	$ 45.45M	$ 94.55M	$ -32.05M	$ 17.28M	$ 5.88M
Operating Income	$ -40.34M	$ -45.45M	$ -94.55M	$ -32.05M	$ -17.28M	$ -5.88M
Net Non Operating Interest Income Expense	$ -4.20M	$ -4.20M	$ -1.50M	-	-	-
Other Income Expense	$ 229.00K	$ 229.00K	$ 506.00K	$ -7.00K	$ 11.00K	-
Pretax Income	$ -45.67M	$ -45.67M	$ -95.06M	$ -32.04M	$ -17.27M	$ -5.88M
Tax Provision	$ 30.00K	$ 30.00K	$ 25.00K	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -45.70M	$ -45.70M	$ -95.08M	$ -32.04M	$ -17.27M	$ -5.88M
Basic EPS	$ -1.52	$ -1.34	$ -4.09	$ -2.64	$ -1.04	$ -0.36
Diluted EPS	$ -1.52	$ -1.34	$ -4.09	$ -2.64	$ -1.04	$ -0.36
Basic Average Shares	$ 136.31M	$ 34.08M	$ 23.27M	$ 12.13M	$ 16.53M	$ 16.53M
Diluted Average Shares	$ 136.31M	$ 34.08M	$ 23.27M	$ 12.13M	$ 16.53M	$ 16.53M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 40.34M	$ 45.45M	$ 94.55M	$ -32.05M	$ 17.28M	$ 5.88M
Net Income From Continuing And Discontinued Operation	$ -45.70M	$ -45.70M	$ -95.08M	$ -32.04M	$ -17.27M	$ -5.88M
Normalized Income	$ -6.03M	$ -30.78M	-	-	$ -17.27M	$ -5.88M
Interest Expense	-	-	-	-	-	-
EBIT	$ -38.01M	$ -38.01M	$ -93.56M	$ -32.04M	$ -17.28M	$ -5.88M
EBITDA	$ -38.83M	$ -38.83M	$ -93.74M	$ -32.02M	$ -17.26M	$ -5.88M

Currency in USD

Elevation Oncology Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing